FDA Lists Wegovy and Ozempic as Available

The FDA announced on Wednesday that all doses of Novo Nordisk's weight-loss drug Wegovy and diabetes medication Ozempic are now available in the U.S., marking a significant step in addressing a shortage that has persisted since March 2022. Novo Nordisk confirmed that these drugs are being regularly shipped to wholesalers, although patients may still face variability in prescription fulfillment at pharmacies. The Danish pharmaceutical company has invested heavily to increase production capacity, citing ongoing communication with the FDA as a key factor in resolving supply issues. With all doses now listed as available, the FDA may soon remove these medications from its shortage list, which could impact compounding pharmacies that have been providing custom versions. Both Wegovy and Ozempic contain semaglutide and have gained popularity for their efficacy in treating obesity and diabetes. However, Novo Nordisk has cautioned that even with improved availability, patients may not always find their prescriptions immediately filled at specific pharmacies.